The CRO for CNS
The only CRO focused exclusively on central nervous system (CNS) drug development, an area of significant unmet need.
Substance Use Disorders
Rare and Ultra-Rare CNS Diseases
Bringing new therapies to patients living with mental health, neurological and substance use disorders.
Experience, Scientific Knowledge and Operational Expertise Combine With Accountability, Responsibility and Integrity
Latest News & Updates
Cybin and Clinilabs Granted Schedule I DEA License for CYB003 Phase 1/2a First-In-Human Clinical Trial
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, and its [...]
A phase 1 double-blind, placebo-controlled study of zuranolone (SAGE-217) in a phase advance model of insomnia in healthy adults
Pharmaceutical companies have used experimental models of transient insomnia to assess the sleep-promoting effects of investigational drugs for over [...]
Clinilabs Drug Development Corporation Joins Decentralized Trials & Research Alliance (DTRA) to Accelerate Clinical Trials
Clinilabs and the DTRA Aim to Dramatically Increase Access for All Patient Populations in Clinical Trials and Research June 7, [...]
Connect With Us
Connect with us online, or come visit us at
an upcoming industry event!
A PATIENT-CENTRIC APPROACH TO CLINICAL TRIALS
Volunteers & Patients
We empower study participants by educating them about clinical research, enabling them to make informed decisions regarding study participation.
NEW POSSIBILITIES FOR
Clinilabs collaborates with investigator sites worldwide to conduct clinical trials that lead to new drug approvals. Become an investigator in our global network!